
Opinion|Videos|April 15, 2025
The VISIBLE Study: Understanding Comorbidities in Psoriasis Across All Skin Tones
Author(s)Aaron Farberg, MD
An expert discusses how the VISIBLE study examined comorbidity burden in moderate to severe psoriasis across all skin tones, addressing disparities in research. It aimed to highlight unmet needs and improve understanding of disease impact in diverse populations.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the key background of the VISIBLE study, which examined the burden of comorbidities in participants with moderate to severe psoriasis across all skin tones?
- What do you believe was the impetus for this study?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

Obinutuzumab (Gazyva) led to complete remission of proteinuria in more patients than tacrolimus did, according to the FDA.

Infectious disease and urology clinicians described unclear treatment goals, infusion limits, and access barriers for newer UTI agents.

New ACACIA-HCM analyses at HCMS 2026 add imaging and quality-of-life data as Cytokinetics readies an FDA filing in nonobstructive HCM.

An oral SERD plus everolimus cut the risk of progression or death by 62% in ESR1-mutated advanced breast cancer.

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.
Advertisement
Advertisement
Trending on AJMC
1
Emerging Threats to Cell and Gene Therapy Access
2
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
3
FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer
4
FDA Approves Secukinumab as First Anti–IL-17 Biologic for PMR
5

